Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Edding Genor Group Holdings PB Ratio Related Terms
Edding Genor Group Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edding Genor Group Holdings PB Ratio Chart
Edding Genor Group Holdings Annual Data
Trend
Dec24
Dec25
PB Ratio
0.00
0.00
Edding Genor Group Holdings Semi-Annual Data
Dec24
Dec25
PB Ratio
0.00
0.00
HKSE:06998 vs ZTS: PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Edding Genor Group Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edding Genor Group Holdings PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Edding Genor Group Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Edding Genor Group Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Edding Genor Group Holdings (HKSE:06998) has a PB Ratio of 0.72 as of Aug. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Edding Genor Group Holdings and its competitors. According to the industry distribution chart, Edding Genor Group Holdings ranks #140 out of 918 companies in the Drug Manufacturers industry, placing it in the top 15.3%.
Is Edding Genor Group Holdings' PB Ratio too high?
Edding Genor Group Holdings' current PB Ratio is 0.72. The Drug Manufacturers industry median PB Ratio is 1.98. Edding Genor Group Holdings' value of 0.72 is 63.6% below this industry median. Based on the distribution chart, Edding Genor Group Holdings ranks #140 out of 918 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Edding Genor Group Holdings has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Edding Genor Group Holdings' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Edding Genor Group Holdings ranks #140 out of 918 companies for PB Ratio. This places Edding Genor Group Holdings in the top 15% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.98. Edding Genor Group Holdings' value of 0.72 is 63.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.98, based on 918 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edding Genor Group Holdings's current PB Ratio of 0.72 is 63.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Edding Genor Group Holdings and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edding Genor Group Holdings's current PB Ratio is 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edding Genor Group Holdings stock overvalued right now?
Edding Genor Group Holdings (HKSE:06998) has a current PB Ratio of 0.72. The current PB Ratio is 0.72 and 63.6% below the Drug Manufacturers industry median of 1.98. Edding Genor Group Holdings' overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Edding Genor Group Holdings (HKSE:06998), the current PB Ratio is 0.72 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Edding Genor Group Holdings Ltd is an integrated specialty biopharmaceutical company, focusing on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. Through the acquisition of branded drug assets from multinational pharmaceutical companies (MNCs) and licensing in development and commercialisation rights of patented drugs from international biopharmaceutical companies, it has established a portfolio of originator-branded and other drugs. The company has two reportable operating segments: Manufacturing and Distribution, which generates the maximum revenue, and Research and development. Geographically, it derives maximum revenue from the Chinese mainland, and the rest from the USA and other markets.
15GF Score
Get the complete analysis for HKSE:06998
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06998 has been successfully added to your 
